Researchers dive into why scleroderma and lung hypertension weaken the heart

NCT ID NCT04610788

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked at 43 adults with scleroderma or unexplained pulmonary arterial hypertension (PAH) to understand why the right side of the heart weakens. Researchers collected blood and tissue samples during routine procedures and measured heart function over 6 months. The goal was to learn how standard PAH treatment affects the heart, not to test a new therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse scleroderma Familial Primary Pulmonary Hypertension idiopathic pulmonary arterial hypertension pulmonary arterial hypertension pulmonary systemic sclerosis scleroderma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States